Bimatoprost eluting contact lens - MediPrint Ophthalmics
Alternative Names: LL-BMT1Latest Information Update: 12 Feb 2025
At a glance
- Originator Leo Lens Pharma
- Developer MediPrint Ophthalmics
- Class Amides; Antiglaucomas; Lipids; Prostaglandins; Small molecules
- Mechanism of Action Prostaglandin F2alpha receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Glaucoma; Ocular hypertension
Most Recent Events
- 06 Feb 2025 MediPrint anticipates meeting with US FDA for phase-III clinical studies for Glaucoma and Ocular hypertension
- 31 Dec 2024 MediPrint Ophthalmics has patent protection for proprietary chemistry related to the sustained delivery of prostaglandins from contact lenses in USA
- 06 Mar 2024 Updated efficacy and adverse events data from the phase IIb SIGHT-2 trial in Glaucoma released by MediPrint Ophthalmics